Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 51 No. 2
PSYCHOPHARMACOLOGY BULLETIN

VOL 51 No. 2

Articles in This Issue

ORIGINAL RESEARCH

Development of a Patient-Centered Software System to Facilitate Effective Management of Bipolar Disorder

Charles L Bowden, Richard Priesmeyer, Mauricio Tohen, Vivek Singh, Joseph R Calabrese, Terry Ketter, Andrew Nierenberg, Michael E Thase, Gregg Siegel, Leslie H Siegel, Jim Mintz, Rif S El-Mallakh, Susan L McElroy, Melissa Martinez
Objective: Self-management of bipolar disorder (BD) is an important component of treatment. Methods: We developed a patient-centered computational software system based on concepts from nonlinear systems (chaos) theory with mobile access to assist in managing...
Pages 8-19 Read Article
ORIGINAL RESEARCH

Clozapine Prolongs Cortical Silent Period in Patients with Treatment- Resistant Schizophrenia

Atsuhiro Miyazawa, Nobuhisa Kanahara, Yusuke Nakata, Satoshi Kodama, Hiroshi Kimura, Atsushi Kimura, Yasunori Oda, Hiroyuki Watanabe, Masaomi Iyo
Objectives: Although clozapine exhibited high efficacy for treating the symptoms of patients with treatment-resistant schizophrenia (TRS), its precise action mechanisms have not been fully understood. Recently, accumulating evidence has suggested the presence of abnormalities in...
Pages 20-30 Read Article
ORIGINAL RESEARCH

Impact of the Omics-Based Biomarkers on the Mirtazapine’s Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder

MS Zastrozhin, VYu Skryabin, VYu Smirnov, AK Zastrozhina, EV Kaverina, DA Klepikov, EA Grishina, KA Ryzhikova, IV Bure, EA Bryun, DA Sychev
Introduction: Mirtazapine is commonly administered to patients with recurrent depressive disorder. Some of these patients do not show adequate response to the therapy with mirtazapine, whereas many of them experience dose-dependent adverse drug reactions. Previous...
Pages 31-42 Read Article
ORIGINAL RESEARCH

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812

Azmi Nasser, Tesfaye Liranso, Toyin Adewole, Nicholas Fry, Joseph T. Hull, Fatima Chowdhry, Gregory D. Busse, Zare Melyan, Andrew J. Cutler, Robert L. Findling, Stefan Schwabe
Objectives: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in pediatric subjects with ADHD. Here, we report the results of a fourth trial. Methods: Eligible adolescent subjects (N = 297) were...
Pages 43-64 Read Article
REVIEW ARTICLE

Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice

Amber N Edinoff, Natalie W Wu, Benjamin S Maxey, Amy L Ren, Kenna N Leethy, Brook Girma, Amira Odisho, Jessica S Kaye, Aaron J Kaye, Adam M Kaye, Alan D Kaye, George Mychaskiw, Omar Viswanath, Ivan Urits
Mood and psychotic disorders are a group of illnesses that affect behavior and cognition. Schizophrenia is characterized by positive symptoms, such as delusions and hallucinations, as well as negative symptoms. Major depressive disorder (MDD) is...
Pages 69-95 Read Article
REVIEW ARTICLE

Lamotrigine and Stevens-Johnson Syndrome Prevention

Amber N. Edinoff, Long H. Nguyen, Mary Jo Fitz-Gerald, Erin Crane, Kyle Lewis, Samantha St Pierre, Alan D. Kaye, Adam M. Kaye, Jessica S. Kaye, Rachel J. Kaye, Sonja A. Gennuso, Giustino Varrassi, Omar Viswanath, Ivan Urits
Stevens-Johnson Syndrome (SJS) is a rare life-threatening condition characterized by severe mucocutaneous epidermal necrolysis and detachment of the epidermis. The condition centers around a delayed-type hypersensitivity reaction with a complex etiology stemming from a variety...
Pages 96-114 Read Article
REVIEW ARTICLE

Brexanolone to Treat Postpartum Depression in Adult Women

Elyse M Cornett, Lauren Rando, Austin M Labbé, Wil Perkins, Adam M Kaye, Alan David Kaye, Omar Viswanath, Ivan Urits
ZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third...
Pages 115-130 Read Article
REVIEW ARTICLE

Hyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications

Amber N Edinoff, Nancy S Silverblatt, Hayley E Vervaeke, Cassidy C Horton, Eden Girma, Alan D Kaye, Adam Kaye, Jessica S Kaye, Andrew J Garcia, Elisa E Neuchat, Treniece N Eubanks, Giustino Varrassi, Omar Viswanath, Ivan Urits
Infertility, the inability to establish a clinical pregnancy after 12 months of regular unprotected sexual intercourse, is caused by a wide variety of both male and female factors. Infertility is estimated to affect between 8–12%...
Pages 131-148 Read Article